Response to Letter Regarding Article, “Fibroblast Growth Factor 23 and Risk of Incident Stroke in Community-Living Adults”
We thank Drs Zou and Zheng for their comments.1 We agree that future research will need to establish whether measuring fibroblast growth factor 23 may be useful for reducing stroke rates, either as a biomarker for improving cardioembolic stroke risk stratification or potentially as a target of therapy.
Orlando M. Gutiérrez, MD, MMSc
Department of Medicine
University of Alabama at Birmingham
Stroke welcomes Letters to the Editor and will publish them, if suitable, as space permits. Letters must reference a Stroke published-ahead-of-print article or an article printed within the past 3 weeks. The maximum length is 750 words including no more than 5 references and 3 authors. Please submit letters typed double-spaced. Letters may be shortened or edited.
- © 2015 American Heart Association, Inc.
- Zou L,
- Zheng S.